Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 40Thoracic 3Sarcoma 1Head & Neck 1Gynecologic 1Genitourinary 1Dermatologic 1

Conditions

Squamous Cell Carcinoma of Head and Neck 2Head and Neck Neoplasms 2Stomach Neoplasms 1Sarcoma, Alveolar Soft Part 1Neoplasm Metastasis 1Esophageal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Biliary Tract Neoplasms 1

Interventions

pembrolizumab 30Nivolumab 11atezolizumab 8Docetaxel 8Cisplatin 7Carboplatin 7Gemcitabine 6fludarabine 5Trastuzumab 5Paclitaxel 5Ipilimumab 5Fluorouracil 5Cyclophosphamide 5spartalizumab 4cemiplimab 4avelumab 4Polymerase Chain Reaction 4Cetuximab 4Capecitabine 4Bevacizumab 4130-nm albumin-bound paclitaxel 4aldesleukin 3Taxes 3Oxaliplatin 3Magnetic Resonance Spectroscopy 3Leucovorin 3Interleukin-2 3Gene Expression Profiling 3Drug Therapy 3Biopsy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Stomach Neoplasms × Ramucirumab × Head & Neck × Clear all
NCT04999761 2024-09-25

AB122 Platform Study

Taiho Pharmaceutical Co., Ltd.

Phase 1 Recruiting
917 enrolled
GastrointestinalHead & NeckSarcomaThoracic

Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasm Metastasis, Stomach Neoplasms, Colorectal Neoplasms, Sarcoma, Alveolar Soft Part

Data powered by HemOnc (CC BY 4.0) Colophon âš¡